Stock Screener App

Frei -

Installieren

0.478

0.52% -0.0025

after-market

Handel nachbörslich: .48 0.002 +0.42%

Pasithea Therapeutics Corp (KTTA)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten

Pasithea Therapeutics Company Profile & Introduction - Moomoo

Pasithea Therapeutics Corp reports results for the quarter ended June 30Earnings Summary - TradingView

Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView

KTTA: Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M - TradingView

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan

Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView

Pasithea Therapeutics Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026) - Stock Titan

Pasithea Therapeutics (KTTA) Edges Higher: Micro-Cap Biotech Approaches Key Resistance at $0.48Corrective Wave - dars.gov.et

Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A - stocktitan.net

Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote - Stock Titan

Pasithea Therapeutics Corp (KTTA) Cash Flow - TradingKey

Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey

Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

KTTA|Pasithea Therapeutics Corp|Price:0.452|Chg%:-0.003 - TradingKey

Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Pasithea Therapeutics Corp. Revenue Breakdown – NASDAQ:KTTA - TradingView

KTTA|Pasithea Therapeutics Corp|Price:0.455|Chg%:-0.025 - TradingKey

Pasithea Therapeutics (KTTA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise Amid Revenue AbsenceAnnual Report - po-news-eg.net

Pasithea Therapeutics Corp. (KTTA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Pasithea Therapeutics Corp. (KTTA) stock price, news, quote and history - Yahoo Finance UK

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology Congress 2026 - Investing News Network

Pasithea Therapeutics (KTTA) Registration filing Summary - Quartr

Pasithea Therapeutics (KTTA) Proxy filing Summary - Quartr

Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors - Quiver Quantitative

Pasithea Therapeutics Announces Presentation of PAS-004 - GlobeNewswire

Pasithea's PAS-004 Study of Advanced Solid Tumors Gets ESMO Poster Slot - Stock Titan

New Strong Buy Stocks for July 20th - Yahoo Finance

Kartik Krishnan Net Worth (2026) - GuruFocus

Pasithea Therapeutics (KTTA) Tests Support Zone as Modest Decline ContinuesWyckoff Upthrust - dars.gov.et

Pasithea Therapeutics (KTTA) Edges Lower as Stock Hovers Near Support ZoneTriangle Correction - dars.gov.et

Pasithea Therapeutics to present at B. Riley Mi... - Pluang

Pasithea management to meet investors at B. Riley health summit in Boston - Stock Titan

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - GlobeNewswire

Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Narrowing Losses Surprise, But Stock Slips on Revenue AbsenceEstimate Dispersion - dars.gov.et

KTTA Q1 2026 Earnings: Shares Surge on Better-Than-Expected Loss and Operational ProgressRevenue Growth Outlook - dars.gov.et

Pasithea Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock SurgeTax Rate Impact - dars.gov.et

Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan

Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView

Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK

Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa

Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget

Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network

Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan

symbol__ Stock Quote Price and Forecast - CNN

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Price to earnings forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA) - TradingView

KTTA Forecast — Price Target — Prediction for 2027 - TradingView

Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings - TradingView

Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa

Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan

Major Investor Quietly Boosts Stake in Pasithea Therapeutics - TipRanks

Pasithea Therapeutics Corp. Warrants (KTTAW) Live Share Price, Invest From India - INDmoney

MRNA

$64.46

1.80%

ROIV

$36.24

0.11%

RPRX

$59.45

1.45%

INSM

$128.32

3.70%

ALNY

$224.60

1.77%

ONC

$362.51

4.33%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters